Pteryxin [CAS 13161-75-6]

Pteryxin ((+) -Pteryxin) is an orally active multi-target inhibitor that targets NF-κB, MAPK, NLRP3 inflammasome, and Nrf2/ARE pathways. Pteryxin is also a BChE inhibitor (IC50=12.96 μg/mL) with a low inhibitory efficiency on AChE. Pteryxin inhibits the Ca2+-calcineurin-NFATc1 pathway by blocking NF-κB/MAPK signaling, inhibiting NLRP3 inflammasome activation, and reducing ROS generation, and activates Nrf2-mediated antioxidant enzyme expression. Pteryxin has anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin can be used in the study of inflammatory diseases, osteoporosis, diabetes, and Alzheimer's disease[1][2][3][4][5].

[13161-75-6]

C21H22O7

386.4

C/C=C(C)\C(O[C@@H]1C2=C3C(C=CC(O3)=O)=CC=C2OC(C)(C)[C@@H]1OC(C)=O)=O

Cholinesterase (ChE) ; Keap1-Nrf2; NF-κB; NOD-like Receptor (NLR) ; Nuclear Factor of activated T Cells (NFAT) ; p38 MAPK; Reactive Oxygen Species (ROS)

AChE; BChE; NLRP3

99.96

DMSO : 100 mg/mL (ultrasonic)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature

H302, H315, H319, H335

H302, H315, H319, H335